| Clinical data | |
|---|---|
| Other names | Fosfenamine; N-Methyldopamine 4-O-phosphate; Epinine 4-O-phosphate; SIM-2055; Z-2055 |
| Routes of administration | Oral |
| Drug class | Dopamine receptor agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C9H14NO5P |
| Molar mass | 247.187 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Fosopamine (INNTooltip International Nonproprietary Name; developmental code names SIM-2055, Z-2055; also known as fosfenamine or N-methyldopamine 4-O-phosphate) is a dopamine receptor agonist of the phenethylamine and catecholamine families which was under development for the treatment of hypertension but was never marketed. It is taken orally. Fosopamine is a prodrug of epinine (N-methyldopaine) and is said to be selectively metabolized into epinine in the kidneys. The drug was being developed by AstraZeneca and Zambon Group SpA. It reached phase 2 clinical trials prior to the discontinuation of its development.
| D1-like |
| ||||||
|---|---|---|---|---|---|---|---|
| D2-like |
| ||||||
| Phenethylamines |
| ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amphetamines |
| ||||||||||||||||
| Phentermines |
| ||||||||||||||||
| Cathinones |
| ||||||||||||||||
| Phenylisobutylamines (and further-extended) |
| ||||||||||||||||
| Catecholamines (and close relatives) |
| ||||||||||||||||
| Cyclized phenethylamines |
| ||||||||||||||||
| Related compounds |
| ||||||||||||||||